HDAC Inhibitors: A novel anti-inflammatory approach
Histone Deacetylases are a family of metalloenzymes that are able to Deacetylase histones, leading to repression of gene expression.

In addition to their application in oncology, HDAC inhibitors have potential use in autoimmune and inflammatory disorders such as rheumatoid arthritis, due to their ability to inhibit the expression of pro-inflammatory cytokines such as TNF-alpha. Chroma is developing HDAC inhibitors that are distinct from its oncology candidate using its proprietary cell accumulation approach that facilitates selective accumulation of drug in macrophages, key drivers of inflammatory processes. Chroma expects to nominate a HDAC inflammation development candidate during 2007. Chroma has also identified pan-cell HDAC inhibitors utilising its proprietary cell accumulation approach that are suitable for use as inhaled therapies for inflammation-driven respiratory conditions such as COPD.